UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 238

Sortiert nach

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Annals of oncology, 2019-06, Vol.30 (6), p.1017-1017

2019

Link zum Volltext

Verfügbarkeit prüfen

Carboplatin: current status and future prospects

Cancer treatment reviews, 1988-06, Vol.15, p.17-32

1988

Link zum Volltext

Verfügbarkeit prüfen

Overview of Taxol safety

Journal of the National Cancer Institute. Monographs, 1993 (15), p.131

1993

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for doxorubicin-induced congestive heart failure

Annals of internal medicine, 1979-11, Vol.91 (5), p.710

1979

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-14-02: A Phase 3 Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel vs. Trastuzumab and Paclitaxel for 1st Line Therapy of HER2+ Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-14-02

2010

Link zum Volltext

Verfügbarkeit prüfen

Cis-diamminedichloroplatinum (II). A new anticancer drug

Annals of internal medicine, 1977-06, Vol.86 (6), p.803

1977

Link zum Volltext

Verfügbarkeit prüfen

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

Journal of clinical oncology, 1992-02, Vol.10 (2), p.257-263

1992

Link zum Volltext

Verfügbarkeit prüfen

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Annals of oncology, 2014-03, Vol.25 (3), p.592

2014

Link zum Volltext

Verfügbarkeit prüfen

Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group

Cancer, 1988-09, Vol.62 (6), p.1061-1065

1988

Link zum Volltext

Verfügbarkeit prüfen

Satraplatin: A new treatment option for patients with hormone refractory prostate cancer

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4802-4802

2005

Link zum Volltext

Verfügbarkeit prüfen

In vitro determination of the antitumor activity of chemotherapy

Revue médicale de Bruxelles, 1983-03, Vol.4 (3), p.147

1983

Link zum Volltext

Verfügbarkeit prüfen

Cancer therapy--economic aspects

הרפואה, 1995-02, Vol.128 (3), p.182

1995

Link zum Volltext

Verfügbarkeit prüfen

Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial

Cancer chemotherapy and pharmacology, 1988-01, Vol.22 (4), p.316-320

1988

Link zum Volltext

Verfügbarkeit prüfen

Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck

Cancer, 1987-09, Vol.60 (6), p.1173-1177

1987

Link zum Volltext

Verfügbarkeit prüfen

Clinical status of carboplatin

Oncology (Williston Park, N.Y.), 1987-07, Vol.1 (5), p.61

1987

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of carboplatin given on a five-day intravenous schedule

Journal of clinical oncology, 1983-10, Vol.1 (10), p.621-626

1983

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of tallysomycin S10b in patients with advanced colorectal cancer

Cancer chemotherapy and pharmacology, 1990-01, Vol.26 (3), p.221-222

1990

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer

Journal of clinical oncology, 1984-04, Vol.2 (4), p.275-281

1984

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy principles in the treatment of prostatic cancer

The Prostate, 1984, Vol.5 (1), p.55-62

1984

Link zum Volltext

Verfügbarkeit prüfen

Predictive tests and infrequent events in cancer chemotherapy

Recent results in cancer research, 1984, Vol.94, p.174

1984

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of tallysomycin S10b in patients with advanced head and neck cancer

Investigational new drugs, 1990-08, Vol.8 (3), p.325-328

1990

Link zum Volltext

Verfügbarkeit prüfen

Batanopride (BMY-25801) : a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

Cancer treatment reviews, 1990-09, Vol.17 (2-3), p.319-327

1990

Link zum Volltext

Verfügbarkeit prüfen

Batanopride (BMY-25801): A new 5-HT 3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

Cancer treatment reviews, 1990-09, Vol.17 (2), p.319-327

1990

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy of solid tumors. The role of cisplatin in today's chemotherapy

Revue médicale de Bruxelles, 1983-04, Vol.4 (4), p.213

1983

Link zum Volltext

Verfügbarkeit prüfen

Role of chemotherapy in the treatment of bronchopulmonary neoplasms

Bruxelles medical, 1975-09, Vol.55 (9), p.463

1975

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(237)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(201)
Science & Technology
(105)
Life Sciences & Biomedicine
(104)
Oncology
(83)
Female
(81)
Male
(71)
Middle Aged
(59)
Adult
(56)
Drug Evaluation
(55)
Dentistry
(54)
Aged
(47)
Neoplasms - Drug Therapy
(41)
Antineoplastic Agents - Therapeutic Use
(36)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Antineoplastic Agents
(32)
Pharmacology. Drug Treatments
(32)
Animals
(26)
Chemotherapy
(22)
Clinical Trials As Topic
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Carboplatin: current status and future prospects

Overview of Taxol safety

Risk factors for doxorubicin-induced congestive heart failure

Abstract P6-14-02: A Phase 3 Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel vs. Trastuzumab and Paclitaxel for 1st Line Therapy of HER2+ Metastatic Breast Cancer

Cis-diamminedichloroplatinum (II). A new anticancer drug

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group

Satraplatin: A new treatment option for patients with hormone refractory prostate cancer

In vitro determination of the antitumor activity of chemotherapy

Cancer therapy--economic aspects

Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial

Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck

Clinical status of carboplatin

Phase I study of carboplatin given on a five-day intravenous schedule

Phase II study of tallysomycin S10b in patients with advanced colorectal cancer

Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer

Chemotherapy principles in the treatment of prostatic cancer

Predictive tests and infrequent events in cancer chemotherapy

Phase II study of tallysomycin S10b in patients with advanced head and neck cancer

Batanopride (BMY-25801) : a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

Batanopride (BMY-25801): A new 5-HT 3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

Chemotherapy of solid tumors. The role of cisplatin in today's chemotherapy

Role of chemotherapy in the treatment of bronchopulmonary neoplasms

Suchergebnisse filtern